Purpose: To evaluate the reduction in horizontal dimension of primary pterygium after subconjunctival Bevacizumab injection.

Materials and methods: Subjects with primary pterygium were randomized to study group (subconjunctival Bevacizumab injection group) and control group. The inclusion criteria were adults (age older than 18) with primary pterygium less than 3 millimeters in horizontal dimension. The primary outcome is the reduction of horizontal dimension at 1 week, 1 month, 3 months and 6 months.

Results: Fifty-nine subjects with primary pterygium were enrolled in this study. The mean age is 56.25 years (± 12.90). Forty-seven subjects were female, the remaining were male. Mean size reduction in the Bevacizumab group was 0.517 mm. (±0.301), 0.710 mm. (±0.359), and 0.790 mm. (±0.361) at 1 month, 3 months and 6 months respectively. Mean size reduction in control group was -0.067 mm. (±0.258), -0.010 mm. (±0.304) and -0.003 mm. (±0.366) at 1 month, 3 months, and 6 months respectively. The p-value of difference in pterygium size reduction between Bevacizumab group and control group is less than 0.001 at all visit.

Conclusion: The reduction of horizontal dimension in primary pterygium at 1 month, 3 months and 6 months is significantly greater in those who received subconjunctival bevacizumab injection compared to the control group.